Share on StockTwits

Stock analysts at MLV & Co
increased their price objective on shares of TG Therapeutics (NASDAQ:TGTX) from $10.00 to $16.00 in a report issued on Wednesday. The firm currently has a “buy” rating on the stock. MLV & Co
‘s price target points to a potential upside of 60.16% from the company’s current price.

The analysts wrote, “We now raise our PT on TGTX to $16 (vs. our prior $10) on: 1) flawless execution with lead assets TG-1101 and TGR-1202; 2) a favorable view of TGTX’s in-licensing of a novel IRAK4 inhibitor program; and 3) a strong belief that data for TGTX’s proprietary ’1101 + ’1202 combination at next month’s Pan Pacific Lymphoma Conference will be positive. Thus, ahead of a significant upcoming catalyst, and a view that TGTX will ultimately present as a very attractive takeout candidate, we maintain our Buy rating and reiterate TGTX as one of our top ideas.”

Several other analysts have also recently commented on the stock. Analysts at Ladenburg Thalmann set a $18.00 price target on shares of TG Therapeutics in a research note on Monday, June 16th. Separately, analysts at Roth Capital reiterated a “focus list” rating on shares of TG Therapeutics in a research note on Thursday, May 22nd. Finally, analysts at Brean Capital initiated coverage on shares of TG Therapeutics in a research note on Friday, April 4th. They set a “buy” rating and a $13.00 price target on the stock. One research analyst has rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $13.18.

TG Therapeutics (NASDAQ:TGTX) traded up 9.61% during mid-day trading on Wednesday, hitting $10.95. The stock had a trading volume of 327,906 shares. TG Therapeutics has a 52 week low of $2.97 and a 52 week high of $11.56. The stock has a 50-day moving average of $7.18 and a 200-day moving average of $5.99. The company’s market cap is $410.4 million.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, May 12th. The company reported ($0.25) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.19) by $0.06. On average, analysts predict that TG Therapeutics will post $-1.04 earnings per share for the current fiscal year.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.